Lymphangiosarcoma (562) cell line

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Lymphangiosarcoma (562) cell line
• Alternate name: 562 cell line
• Cancer: Sarcoma
• Cancers detailed: Angiosarcoma/Lymphangiosarcoma
• Research fields: Cancer;Drug development
• Parental cell: N/A
• Organism: Mouse
• Disease: Cancer
• Model: Tumour line
• Conditional: Yes
• Conditional description: Cells derived from C57BL/6 mouse carrying paw cutaneous tumor through tamoxifen -induced Tsc1 gene deletion in endothelial cells with Scl-Cre
• Description: Angiosarcoma/lymphangiosarcoma is a rare cancer that currently has no effective treatment. The mechanism of angiosarcoma development is largely unknown, and there is no animal model for the disease with molecularly defined pathogenesis. Loss of Tsc1 can cause hyper-activation of mTORC1 signaling in endothelial cells, which results in the development of lymphatic malformation (LM) and progression to vascular tumors that recapitulate salient features of human lymphangiosarcoma (LAS), including local invasion and systemic metastasis.

Target Details

• Target: Angiosarcoma/Lymphangiosarcoma

Handling

• Growth medium: Dulbeccoâ?‚€?‚™s modified Eagleâ?‚€?‚™s medium containing 10% fetal bovine serum, supplemented with 300 USP/L porcine heparin (Millipore-Sigma), 25 mM HEPES, 50 mg/L endothelial cell growth supplement (Corning), 1% MEM non-essential amino acids (gibco) and 1% penicillinâ?‚€?‚“streptomycin (gibco) and grown in 5% CO2 at 37 Â?‚°C.

References

• Yang et al. 2020. Br J Cancer. 122(12):1791-1802. PMID: 32336756.
• Sun et al. 2015. Cancer Cell. 28(6):758-772. PMID: 26777415.